- Home
- BCTX vs ADAP Comparison
BCTX vs ADAP Comparison
Compare BCTX & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- ADAP
- Stock Information
- Founded
- BCTX 2014
- ADAP 2008
- Country
- BCTX Canada
- ADAP United Kingdom
- Employees
- BCTX N/A
- ADAP N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- BCTX Health Care
- ADAP Health Care
- Exchange
- BCTX Nasdaq
- ADAP Nasdaq
- Market Cap
- BCTX 21.8M
- ADAP 21.3M
- IPO Year
- BCTX N/A
- ADAP 2015
- Fundamental
- Price
- BCTX $11.00
- ADAP $0.05
- Analyst Decision
- BCTX Strong Buy
- ADAP Hold
- Analyst Count
- BCTX 1
- ADAP 6
- Target Price
- BCTX $40.00
- ADAP $1.02
- AVG Volume (30 Days)
- BCTX 89.1K
- ADAP 127.2M
- Earning Date
- BCTX 10-16-2025
- ADAP 11-12-2025
- Dividend Yield
- BCTX N/A
- ADAP N/A
- EPS Growth
- BCTX N/A
- ADAP N/A
- EPS
- BCTX N/A
- ADAP N/A
- Revenue
- BCTX N/A
- ADAP N/A
- Revenue This Year
- BCTX N/A
- ADAP N/A
- Revenue Next Year
- BCTX $380.95
- ADAP $24.70
- P/E Ratio
- BCTX N/A
- ADAP N/A
- Revenue Growth
- BCTX N/A
- ADAP N/A
- 52 Week Low
- BCTX $6.00
- ADAP $0.04
- 52 Week High
- BCTX $190.50
- ADAP $0.86
- Technical
- Relative Strength Index (RSI)
- BCTX 45.44
- ADAP 38.17
- Support Level
- BCTX $11.75
- ADAP $0.04
- Resistance Level
- BCTX $13.43
- ADAP $0.09
- Average True Range (ATR)
- BCTX 1.07
- ADAP 0.03
- MACD
- BCTX -0.34
- ADAP -0.02
- Stochastic Oscillator
- BCTX 6.12
- ADAP 5.74
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.